GlaxoSmithKline says net profits drop 13% in Q1

British drugsmaker GlaxoSmithKline said Wednesday that its net profits dropped 13 percent to £1.325 billion (1.616 billion euros, $2.134 billion) in the first quarter from a year earlier.

The result was skewed by the fact GSK had its earnings after tax boosted in the first quarter of 2011 by the sale of its stake in medical testing business Quest Diagnostics.

GSK added in a statement that group revenue rose 1.0 percent to £6.64 billion in the first three months of 2012 compared with the first quarter in 2011.

"This (first) quarter (in 2012) marked continued progress for the group as we returned to reported sales growth," GSK chief executive Andrew Witty said in the company's results statement.

"We remain mindful of the challenges we face given the current global political and economic environment, particularly in relation to pricing on our more established products.

"However, we also continue to see attractive growth opportunities across our businesses and we intend to continue to invest behind them to strengthen the breadth and mix of the group and its future growth prospects," he added.

GSK added that it was raising its 2012 share buyback target to £2.0 billion-£2.5 billion after agreeing in the first quarter to sell a stable of over-the-counter brands to Belgium's Omega Pharma.

Also in the first quarter, GSK said it would create 1,000 jobs and open a new production site in northern England.

Earlier this month meanwhile, the drugs giant bid $2.6 billion for US research partner Human Genome Sciences Inc.

add to favorites email to friend print save as pdf

Related Stories

GlaxoSmithKline posts rising Q3 profits

Oct 26, 2011

British drugmaker GlaxoSmithKline said Wednesday that third-quarter net profit rose seven percent, boosted by growth across its main pharmaceuticals, vaccines and consumer healthcare divisions.

GSK to take $3.4 bln Avandia legal charge

Jan 17, 2011

British drugs firm GlaxoSmithKline said Monday it expects to take a legal charge of £2.2 billion linked to its former blockbuster diabetes product Avandia, sparking a sharp drop in its shares.

Recommended for you

Drug research and development more efficient than expected

7 hours ago

Drug R&D costs have increased substantially in recent decades, while the number of new drugs has remained fairly constant, leading to concerns about the sustainability of drug R&D and question about the factors that could ...

Use new meningitis vaccines only for outbreaks

Feb 26, 2015

(AP)—A U.S. panel on Thursday recommended that two new meningitis vaccines only be used for rare outbreaks, resisting tearful pleas to give it routinely to teens and college students.

New antibiotic avycaz approved

Feb 26, 2015

(HealthDay)—The combination antibiotic Avycaz (ceftazidime-avibactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated infections of the intra-abdominal area or urinary tract, ...

Tagging drugs to fight counterfeit medicines

Feb 25, 2015

The U.S. and other countries are enacting rules to clamp down on the sales of fake pharmaceuticals, which pose a public health threat. But figuring out a system to track and authenticate legitimate drugs still faces significant ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.